Mosunetuzumab, a Full-Length Bispecific CD20/CD3 Antibody, Displays Clinical Activity in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (NHL): Interim Safety and Efficacy Results from a Phase 1 Study

Lihua E. Budde, Nancy L. Bartlett, Scott McClellan et al.|Blood|2018

Cited by 59